je.st
news
Tag: tumor
Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin (RX-5902)
2013-12-30 06:54:32| drugdiscoveryonline News Articles
Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, recently announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate Supinoxin (RX-5902)
Tags: method
treatment
solid
patent
Varian's Calypso Tumor Tracking System Used in Lung, Stomach, and Prostate Cancer Treatments ...
2013-09-30 06:00:00| Industrial Newsroom - All News for Today
Lisbon, Portugal – Clinicians in Lisbon have commenced advanced radiosurgery treatments using Varian's Calypso® 'GPS for the Body' real-time tumor tracking system. Doctors at the 'Champalimaud Center for the Unknown' (CCU) utilized the Calypso system to enhance precision during a radiosurgery treatment that included the world's first clinical use of the new commercially available Calypso lung Beacon® transponder. <br /> <br /> The center has used this method to treat three patients with ...This story is related to the following:Health, Medical and Dental Supplies and EquipmentSearch for suppliers of: Tracking Systems | Radiotherapy Systems |
Tags: system
cancer
tracking
treatments
Lilly Drug Fails to Meet Survival Goal in Breast Tumor Study
2013-09-27 17:01:44| Food - Topix.net
Eli Lilly & Co.' s experimental drug ramucirumab failed to meet its goals for treating breast cancer in a late-stage trial, sending the shares down.
Lilly Drug Fails to Meet Survival Goal in Breast Tumor Study
2013-09-27 02:09:27| Agriculture - Topix.net
Eli Lilly & Co.' s experimental drug ramucirumab failed to meet its goals for treating breast cancer in a late-stage trial, sending the shares down.
Merck KGaA brain tumor drug fails clinical trial
2013-02-25 15:33:17| Biotech - Topix.net
Merck KGaA's Cilengitide, an experimental drug to treat an aggressive type of brain tumor, has failed a large-scale clinical trial, dealing a blow to the German drugmaker's efforts to replenish its pipeline of medicines.
Tags: trial
drug
clinical
brain